2024
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian age
2022
Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial
Sedrak M, Sun C, Ji J, Cohen H, Gross C, Tew W, Klepin H, Wildes T, Dotan E, Freedman R, O'Connor T, Chow S, Fenton M, Moy B, Chapman A, Dale W, Katheria V, Kuderer N, Lyman G, Magnuson A, Muss H. Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial. Journal Of Clinical Oncology 2022, 41: 316-326. PMID: 36455189, PMCID: PMC9839299, DOI: 10.1200/jco.22.01440.Peer-Reviewed Original ResearchConceptsLow relative dose intensityRelative dose intensityAdjuvant chemotherapyHOPE trialDose intensityOlder patientsOlder womenBreast cancer benefitPrespecified secondary analysisCurative-intent treatmentInferior survival outcomesChemotherapy dose intensityKaplan-Meier methodLow performance statusMultivariable logistic regressionLog-rank testOverall survival probabilityToxic side effectsCancer benefitOverall survivalPerformance statusStandard chemotherapySupportive carePrimary outcomeSurvival outcomes
2019
Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.
Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.Peer-Reviewed Original ResearchOverall survivalMultiple myelomaPerformance statusMultivariable Cox survival analysisMedian overall survivalPoor performance statusLines of therapyKaplan-Meier methodCox regression analysisDays of diagnosisWorse overall survivalCox survival analysisLog-rank testReal-world treatmentCommon genetic mutationsHigh-risk mutationsSitu hybridization testingElectronic health recordsISS stageReal-world practiceMedian ageMeier methodOS independentPrimary outcomeSpecific regimens
2017
Use of alternative medicine for cancer and its impact on survival.
Johnson S, Gross C, Park H, Yu J. Use of alternative medicine for cancer and its impact on survival. Journal Of Clinical Oncology 2017, 35: e18175-e18175. DOI: 10.1200/jco.2017.35.15_suppl.e18175.Peer-Reviewed Original ResearchCharlson-Deyo comorbidity scoreConventional cancer treatmentsNational Cancer DatabaseAlternative medicineColorectal cancerCancer treatmentComorbidity scoreCox proportional hazards regressionGreater riskNon-metastatic breastYear of diagnosisAlternative medicine useKaplan-Meier methodSubgroup of patientsAlternative medicine utilizationProportional hazards regressionCancer patient characteristicsDisease-related factorsLog-rank testAnti-cancer treatmentChi-square testPatterns of utilizationHigher socioeconomic statusHormone therapyOverall survival
2015
Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US)
Zeidan A, Wang R, Davidoff A, Gore S, Soulos P, Huntington S, Gross C, Ma X. Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US). Blood 2015, 126: 873. DOI: 10.1182/blood.v126.23.873.873.Peer-Reviewed Original ResearchDisability Status ScoreOverall survivalMyelodysplastic syndromeMDS patientsCost of careStudy cohortLack of associationHistologic subtypeStatus scoreMedicare beneficiariesEnd Results-Medicare databaseProportional hazards regression modelsOverall study cohortMedian overall survivalOutcomes of patientsElixhauser comorbidity scoreDate of diagnosisEntire study cohortKaplan-Meier methodHazards regression modelsDisease-related costsNon-white raceEnd of studyDate of deathMedicare Part A